论文部分内容阅读
目前使用的肺炎球菌菌苗为23价荚膜多糖菌苗,在成人及2岁以上儿童中具有免疫原性,但对2岁以下婴幼儿的免疫效果较差.本文对一种7价肺炎球菌偶联菌苗在婴儿中的安全性、免疫原性和免疫记忆进行了评估.将含7个血清型(6B、14、19F、23F、18C、4和9V)的肺炎球菌与B群脑膜炎球菌外膜蛋白复合物结合,制备出7价肺炎球菌偶联菌苗.0.5ml偶联菌苗中含7个血清型肺炎球菌多糖共11μg及脑膜炎球菌外膜蛋白复合物85μg.选择25名健康婴儿分别于2、4和6月龄时接种0.5ml偶联菌苗,其中20名婴儿于12～15月龄时加强1剂23价肺炎球
The currently used pneumococcal vaccine is a 23-valent capsular polysaccharide vaccine that is immunogenic in adults and children over 2 years of age, but less immunized against infants under the age of 2. In this article, a 7-valent pneumococcal The safety, immunogenicity and immunological memory of the conjugate vaccine in infants were evaluated.Pneumococci with 7 serotypes (6B, 14, 19F, 23F, 18C, 4 and 9V) Cocci outer membrane protein complex to prepare a 7-valent pneumococcal conjugate vaccine .0.5ml conjugate vaccine containing 7 serotypes of pneumococcal polysaccharide 11μg and meningococcal outer membrane protein complex 85μg. Select 25 Healthy infants were vaccinated with 0.5 ml of conjugate vaccine at 2, 4, and 6 months of age, respectively, of which 20 infants were boosted with one dose of 23-valent pneumococcal at 12-15 months of age